Research
GHK-Cu: what it is and what is actually known
GHK-Cu has a large and genuinely interesting laboratory literature behind it. Almost none of it was produced by injecting the compound into people, which is the way it is now being sold.
- The GHK-Cu board scores the sellers that publish a GHK-Cu price, on what each one discloses.
- Set against another compound on the same evidence standard: Injectable GHK-Cu vs copper peptide topicals.
What GHK-Cu is
GHK is a tripeptide — three amino acids, glycine, histidine and lysine, in that order. It occurs naturally in human plasma. Its defining property is that it binds copper tightly, and the copper-bound form, written GHK-Cu, is what the research and the products are about. The copper is not an additive. It is part of what the molecule is understood to do.
The peptide was identified in human plasma decades ago. The work behind that discovery was looking at why plasma from younger donors behaved differently from plasma from older donors in liver-cell cultures. The concentration reported in plasma is described in that literature as declining substantially between young adulthood and later life. No figure for that decline appears here. The numbers circulating in marketing copy are repeated far more often than they are sourced, and a plausible number is worse than no number.
That origin story matters. It is the reason GHK-Cu is marketed as an anti-aging compound rather than as a treatment for anything specific. The claim is not that it fixes a named disease. The claim is that it is a signal your body had more of when you were young.
The laboratory literature is real and it is mostly not in humans
GHK-Cu has been studied for a long time and there is a substantial body of published work on it. In cell culture and in animal models it has been reported to influence fibroblast behavior, collagen and other extracellular matrix production, angiogenesis, and the sequence of events involved in wound repair. There is also gene-expression work describing broad effects on the pathways involved in tissue remodeling.
None of that is fabricated and none of it should be dismissed. It is a coherent mechanistic story, and it explains why the compound attracted serious attention in the first place.
It is also, almost entirely, preclinical. Cells in a dish and healing wounds in animals are where hypotheses come from, not where they are confirmed. The gap between an interesting effect on cultured fibroblasts and a benefit a person can detect is enormous. The history of medicine is largely a record of compounds that cleared the first bar and failed the second. Presenting a preclinical literature as though volume substituted for the missing step is the central problem with how this compound is sold.
The human evidence that does exist is topical and cosmetic
Copper peptides have been used in cosmetic skincare for a long time. There is some human work on topical formulations — creams and serums evaluated for effects on the appearance of skin, wrinkles, firmness and photodamage.
That work should be read for what it is. The studies in this space have generally been small, short, evaluated on appearance-based measures, and frequently conducted or funded by parties with a commercial interest in the product. Cosmetic efficacy testing is a legitimate activity, but it operates to a different standard than clinical trial evidence. It is designed to support a claim about how skin looks, not a claim about what is happening in the body.
It is also, crucially, about a cream. A topical study tells you something about a molecule applied to the surface of skin. It does not transfer to a molecule injected into the body. Treating it as though it does is the specific sleight of hand that lets an injectable product borrow a cosmetic evidence base.
What is being sold, and why the grade is what it is
In the peptide market GHK-Cu is sold as an injectable vial. It is marketed for skin quality, hair growth, connective tissue and joint recovery, lung health, and general anti-aging effects across the whole body. Those are systemic claims about a compound whose human evidence is a topical cosmetic literature and whose mechanistic evidence is preclinical.
GHK-Cu is graded no controlled human evidence. That grade is about the compound as it is actually sold — injected, systemically, for those outcomes. It does not mean nobody has ever studied the molecule. A great deal of work has been published on GHK-Cu. What has not been published is a controlled human trial establishing that injecting it produces any of the results it is being sold for.
That distinction is the reason the tiers are worded the way they are. The tier is not 'no research'. It is 'no controlled human evidence', and it is the honest description of a compound with a rich laboratory file and an empty clinical one.
The copper question the cosmetic literature does not answer
GHK-Cu delivers copper. Copper is an essential trace element, and it is also an element the body regulates carefully, because too much of it is harmful. The systems that handle copper absorbed from food and copper applied to skin are not the systems that handle copper introduced by injection.
That is not a claim that injectable GHK-Cu causes copper overload. No safety assertion is being made in either direction. The point is narrower and more useful. The topical literature used to reassure buyers was never designed to answer a question about systemic copper exposure, because a cream does not raise that question. Where a product changes the route, the old evidence does not automatically cover the new risk, and here nobody has done the work that would.
This page describes what is known about the compound. It carries no dosing information and is not usage guidance.
Where the regulatory question sits
GHK-Cu appears in cosmetic products sold openly in the United States. Whether it may be compounded into an injectable preparation is a completely different regulatory question. That second question is unsettled, and no outcome is stated here.
A reader should also know that a substantial amount of GHK-Cu changes hands as material sold in vials labeled for research use only. That is not a prescription product and not a compounded prescription either. It sits outside the drug supply chain, with no assurance attached about identity, purity, sterility or content.
The presence of a compound in a legal cosmetic is routinely used in marketing as evidence that the injectable version is fine. It is not evidence of that. It is evidence about a cream.
What would change this grade
The bar is not exotic. It is a randomized, placebo-controlled human trial of the injectable product, in the population it is sold to. It would measure one of the outcomes it is sold for, over a period long enough to distinguish a real effect from a temporary one.
GHK-Cu is unusual in this category. It has a plausible mechanism, a long publication record and an identifiable proponent literature. Those are the ingredients that usually precede a trial. The striking thing is that after all this time the trial has not followed, and the market has grown anyway.
If that work appears, the grade moves. Until then, the accurate summary is that GHK-Cu is one of the better-studied compounds in this class and still has nothing controlled behind the way it is being sold.
Key takeaways
- GHK-Cu is a naturally occurring three-amino-acid peptide that binds copper; the copper is part of the active molecule.
- Its substantial published literature is overwhelmingly cell-culture and animal work.
- The human evidence is topical and cosmetic, and does not transfer to an injected product.
- No controlled human trial establishes benefit for the injectable, systemic uses it is marketed for.
- Much of what is sold is material labeled for research use only, outside the prescription supply chain.
Frequently asked questions
Is there any research on GHK-Cu at all?
Yes, a considerable amount. GHK-Cu has been studied for decades in cell culture and in animal models, with published work on fibroblast activity, collagen and extracellular matrix production, blood vessel formation and wound repair. There is also a human literature on topical cosmetic formulations. The grade of no controlled human evidence is not a claim that the molecule is unstudied. It is a claim that no controlled human trial establishes benefit for the injectable, systemic use it is currently sold for.
Do the copper peptide skincare studies apply to injectable GHK-Cu?
No, and this is the most important thing to understand about the compound. A study of a cream tells you about a molecule applied to the surface of the skin. It is evaluated on how skin looks, usually over a short period, and often by a party with a commercial interest. It cannot tell you what happens when the same molecule is injected and distributed through the body, and it was never designed to. An injectable product borrowing a topical evidence base is not supported by it.
Why does the site not print the figure for how much GHK declines with age?
Because the specific numbers circulating in marketing material are repeated far more often than they are sourced. An unverified figure does not get printed here. The underlying observation is described in the founding literature and can be stated qualitatively: reported plasma concentrations of GHK are substantially lower in later life than in young adulthood. A precise-sounding number with nothing behind it would make the page look more authoritative and be worth less.
Is injectable GHK-Cu a prescription product?
A meaningful share of what circulates is material sold in vials labeled for research use only, which is not a prescription drug and not a compounded prescription preparation. It sits outside the drug supply chain entirely, with no assurance about identity, purity, sterility or how much is actually in the vial. Whether GHK-Cu may lawfully be compounded into an injectable preparation is an unsettled question, and no answer to it is asserted here.